article thumbnail

Compounded semaglutide with B12: Benefits and risks

The Checkup by Singlecare

The FDA has given compounding pharmacies and facilities a deadline of April 22, 2025 or May 22, 2025 (depending on the type of compounding pharmacy or facility) to stop offering compounded semaglutide. It remains to be seen how long compounded semaglutide products will be available.

article thumbnail

Insulin statistics 2025

The Checkup by Singlecare

Source: ADA, 2025 Type 2 diabetes Type 2 diabetes accounts for about 94% of diabetes cases in adults in the U.S. ADA, 2025) Men are slightly more likely than women to be diagnosed with Type 2 diabetes. ADA, 2025) Men are slightly more likely than women to be diagnosed with Type 2 diabetes. of Lantus users and 23.1%

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Five Things For Pharmacists To Know About The Treatment Of Mycobacterium Tuberculosis

IDStewardship

Authored By: Aneeka Chavda, MRPharmS, MSc, MCMI, PgDipClinPharm Posted 19 June 2025 Mycobacterium tuberculosis (TB ) is one of the leading causes of death globally. Finally, the use of fluoroquinolones are discussed, especially for drug-resistant or intolerant patients, noting their potential in CNS TB and as part of shorter-course therapies.

article thumbnail

Avatrombopag Receives FDA Approval for Treamtent of Pediatric Patients With Chronic Immune Thrompcytopenia

Pharmacy Times

Common adverse reactions in pediatric patients included viral infections, nasopharyngitis, and cough, but the drug was generally well-tolerated. In pediatric patients with persistent or chronic ITP, the most common adverse reactions (10% or more) included viral infection, nasopharyngitis, cough, pyrexia, and oropharyngeal pain.

article thumbnail

How AI Brings Pharmacogenetics to the Frontline of Precision Medicine

Pharmacy Times

While the European Medicines Agency mandated pre-treatment DPD testing in Europe as early as 2020, and the UK’s National Health Service followed suit the same year, the US only reached a consensus in 2025. Accessed July 21, 2025. Accessed July 21, 2025. Accessed July 21, 2025. European Medicines Agency. link] NHS England.

article thumbnail

FDA Approves Clesrovimab-cfor for Prevention of RSV in Infants

Drug Topics

Additionally, the safety profile of clesrovimab-cfor was seen to be comparable to placebo, with most adverse reactions being mild to moderate. The most common adverse reactions were injection-site erythema, injection-site swelling and rash. June 9, 2025. Accessed June 10, 2025. News Release.

FDA 432
article thumbnail

FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia

Pharmacy Times

Common adverse reactions included gastrointestinal issues, with a low discontinuation rate due to adverse drug reactions. The CRL was received after OLC’s initial Prescription Drug User Fee Act date of June 28, 2025, and cited for deficiencies that are unrelated to OLC itself. June 30, 2025. News release.

FDA 73